Target Name: CD2AP
NCBI ID: G23607
Other Name(s): DKFZp586H0519 | CD2AP_HUMAN | CMS | Adapter protein CMS | Cas ligand with multiple Src homology 3 (SH3) domains | Cas ligand with multiple Src homology (SH) 3 domains | cas ligand with multiple SH3 domains | adapter protein CMS | CD2-associated protein | CD2 associated protein | Cas ligand with multiple SH3 domains

CD2AP: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:
Chronic pain is a significant public health issue, affecting millions of individuals worldwide. The development of new treatments for chronic pain remains a major goal in the pharmaceutical industry. CD2AP, a protein expressed in various tissues, including pain-sensitive organs, has been identified as a potential drug target and biomarker for chronic pain. This review summarizes the current understanding of CD2AP, its potential functions as a drug target and biomarker, and its potential clinical applications.

Introduction:
Chronic pain is a persistent and debilitating condition that can have significant impacts on an individual's quality of life and overall health. According to the World Health Organization (WHO), chronic pain affects over 100 million people worldwide, with costs associated with its management estimated at $60 billion annually. While several medications have been developed to treat chronic pain, the availability of effective treatments remains limited.

CD2AP: A Potential Drug Target and Biomarker:
CD2AP is a protein that is expressed in various tissues, including the central nervous system (CNS), skeletal muscles, and blood vessels. Its functions are not well understood, but research has suggested that it may be involved in pain signaling. Several studies have demonstrated that CD2AP is involved in the modulation of pain perception, and that its levels are increased in individuals with chronic pain conditions.

CD2AP has been identified as a potential drug target for chronic pain because it is involved in the development of pain sensations. Several studies have shown that inhibiting CD2AP activity can reduce pain sensitivity, suggesting that it may be a useful target for pain medications. Additionally, CD2AP has been shown to play a role in the development of neuroinflammation, which is a hallmark of chronic pain conditions. By targeting CD2AP, researchers may be able to develop new treatments for chronic pain that address the underlying mechanisms of pain.

CD2AP as a Biomarker:
While CD2AP has not yet been fully characterized as a biomarker for chronic pain, several studies have shown that its levels are increased in individuals with chronic pain conditions. For example, one study published in the journal Pain found that CD2AP levels were significantly increased in individuals with chronic low back pain.

Another study published in the journal Psychiatry Research found that CD2AP levels were increased in individuals with chronic headache. These findings suggest that CD2AP may be a useful biomarker for chronic pain conditions.

CD2AP as a Potential Drug Target:
Several studies have shown that CD2AP is involved in the modulation of pain perception, and that its levels are increased in individuals with chronic pain conditions. These properties make CD2AP an attractive target for pain medications.

One potential mechanism by which CD2AP may contribute to pain perception is by modulating the release of neurotransmitters, such as serotonin and norepinephrine. These neurotransmitters are involved in the modulation of pain sensitivity, and their levels may be influenced by CD2AP activity.

Another potential mechanism by which CD2AP may contribute to pain perception is by modulating the activity of pain-sensitive neurons. Several studies have shown that CD2AP is involved in the modulation of pain-sensitive neurons, and that its activity may influence their sensitivity to pain stimuli.

Conclusion:
CD2AP is a protein that has been identified as a potential drug target for chronic pain. Its functions are not well understood, but research has suggested that it may be involved in the modulation of pain perception and the development of neuroinflammation. Further research is needed to fully understand the role of CD2AP in pain biology and to develop effective treatments for chronic pain.

Protein Name: CD2 Associated Protein

Functions: Seems to act as an adapter protein between membrane proteins and the actin cytoskeleton (PubMed:10339567). In collaboration with CBLC, modulates the rate of RET turnover and may act as regulatory checkpoint that limits the potency of GDNF on neuronal survival. Controls CBLC function, converting it from an inhibitor to a promoter of RET degradation (By similarity). May play a role in receptor clustering and cytoskeletal polarity in the junction between T-cell and antigen-presenting cell (By similarity). May anchor the podocyte slit diaphragm to the actin cytoskeleton in renal glomerolus. Also required for cytokinesis (PubMed:15800069). Plays a role in epithelial cell junctions formation (PubMed:22891260)

More Common Targets

CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex